The recogition that the vast majority of patients with small cell lung cancer have distant metastatic disease at the time of diagnosis lead to the use of systemic chemotherapy and consequent major improvement in survival, but recently evaluated treatment strategies, integration of large field chest irradiation with chemotherapy lead to the improved the local control and relapse free survival in limited SCLC. Therefore, it is logical to combine the two modalities in an effort to maximize the therapeutic effect. Authors performed the combination chemotherapy of cav (Cyclophosphamide, Adriamycin, and Vincristine) and radiotherapy of primary tumor and regional Iymphatics with prophylactic cranial irradiation in 42 patients of limited SCLC, from Mar. 1978 to Dec. 1982 Seoul National University Hospital. The results are as follows; 1. CR and PR after 2 cycles chemotherapy is 7% and 43%, respectively however, subsequent response to radiotherapy is 38% and 43% in CR and PR. 2. Overall median survival period is 8.6 months. 3. 1 year and 2 years survival rate is 46.3% and 20.5%, respectively. 4. Incidence of proven brain metastasis is 5%.